

Martin Fañnacht

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/560274/publications.pdf>

Version: 2024-02-01

299
papers

22,960
citations

7568

77
h-index

10158

140
g-index

313
all docs

313
docs citations

313
times ranked

13908
citing authors

#	ARTICLE	IF	CITATIONS
1	Personalized Management of Pheochromocytoma and Paraganglioma. <i>Endocrine Reviews</i> , 2022, 43, 199-239.	20.1	127
2	Reassessment of Postural Stimulation Testing as a Simple Tool to Identify a Subgroup of Patients With Unilateral Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e865-e873.	3.6	7
3	S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study. <i>European Journal of Endocrinology</i> , 2022, 186, 25-36.	3.7	41
4	Plasma Steroid Profiling in Patients With Adrenal Incidentaloma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e1181-e1192.	3.6	19
5	Adrenal wash-out CT: moderate diagnostic value in distinguishing benign from malignant adrenal masses. <i>European Journal of Endocrinology</i> , 2022, 186, 183-193.	3.7	20
6	Cardiometabolic Disease Burden and Steroid Excretion in Benign Adrenal Tumors. <i>Annals of Internal Medicine</i> , 2022, 175, 325-334.	3.9	53
7	Liraglutide + PYY3-36 Combination Therapy Mimics Effects of Roux-en-Y Bypass on Early NAFLD Whilst Lacking-Behind in Metabolic Improvements. <i>Journal of Clinical Medicine</i> , 2022, 11, 753.	2.4	4
8	Impact of Lymphadenectomy on the Oncologic Outcome of Patients with Adrenocortical Carcinoma—A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2022, 14, 291.	3.7	10
9	Adrenal functional imaging. <i>Presse Medicale</i> , 2022, 51, 104114.	1.9	3
10	Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures. <i>Endocrine-Related Cancer</i> , 2022, 29, 285-306.	3.1	12
11	Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms using ⁶⁸ Ga-PentixaFor PET. <i>Journal of Nuclear Medicine</i> , 2022, , jnumed.121.263693.	5.0	27
12	Transcriptome in paraffin samples for the diagnosis and prognosis of adrenocortical carcinoma. <i>European Journal of Endocrinology</i> , 2022, 186, 607-617.	3.7	2
13	Targeting 11-Beta Hydroxylase With [131I]IMAZA: A Novel Approach for the Treatment of Advanced Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e1348-e1355.	3.6	5
14	Roux-en-Y Gastric Bypass and Caloric Restriction but Not Gut Hormone-Based Treatments Profoundly Impact the Hypothalamic Transcriptome in Obese Rats. <i>Nutrients</i> , 2022, 14, 116.	4.1	5
15	Improved Diagnostic Accuracy of Clonidine Suppression Testing Using an Age-Related Cutoff for Plasma Normetanephrine. <i>Hypertension</i> , 2022, 79, 1257-1264.	2.7	8
16	Identification of predictive criteria for pathogenic variants of primary bilateral macronodular adrenal hyperplasia (PBMAH) gene <i>ARMC5</i> in 352 unselected patients. <i>European Journal of Endocrinology</i> , 2022, 187, 123-134.	3.7	18
17	Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 499-508.	11.4	55
18	Radiotherapy for Pediatric Adrenocortical Carcinoma—Review of the Literature. <i>Clinical and Translational Radiation Oncology</i> , 2022, , .	1.7	3

#	ARTICLE	IF	CITATIONS
19	FGF/FGFR signaling in adrenocortical development and tumorigenesis: novel potential therapeutic targets in adrenocortical carcinoma. <i>Endocrine</i> , 2022, 77, 411-418.	2.3	6
20	Differences in morbidity and mortality between unilateral adrenalectomy for adrenal Cushing's syndrome and bilateral adrenalectomy for therapy refractory extra-adrenal Cushing's syndrome. <i>Langenbeck's Archives of Surgery</i> , 2022, 407, 2481-2488.	1.9	3
21	ENDOCRINE TUMOURS: Our experience with the management of patients with non-metastatic adrenocortical carcinoma. <i>European Journal of Endocrinology</i> , 2022, 187, R27-R40.	3.7	13
22	EO2401, a novel microbiome-derived therapeutic vaccine for patients with adrenocortical carcinoma (ACC): Preliminary results of the SPENCER study. <i>Journal of Clinical Oncology</i> , 2022, 40, 4596-4596.	1.6	4
23	Preanalytical Considerations and Outpatient Versus Inpatient Tests of Plasma Metanephrines to Diagnose Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3689-e3698.	3.6	4
24	Predictive Value of FDG Uptake in the Remaining Adrenal Gland Following Adrenalectomy for Adrenocortical Cancer. <i>Hormone and Metabolic Research</i> , 2021, 53, 24-31.	1.5	1
25	Data set for reporting of carcinoma of the adrenal cortex: explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting. <i>Human Pathology</i> , 2021, 110, 50-61.	2.0	18
26	Single-cell molecular profiling of all three components of the HPA axis reveals adrenal ABCB1 as a regulator of stress adaptation. <i>Science Advances</i> , 2021, 7, .	10.3	42
27	PKA C α subunit mutation triggers caspase-dependent RIL β subunit degradation via Ser ¹¹⁴ phosphorylation. <i>Science Advances</i> , 2021, 7, .	10.3	4
28	ENSAT registry-based randomized clinical trials for adrenocortical carcinoma. <i>European Journal of Endocrinology</i> , 2021, 184, R51-R59.	3.7	11
29	Circulating microRNA Expression in Cushing's Syndrome. <i>Frontiers in Endocrinology</i> , 2021, 12, 620012.	3.5	11
30	First German Guideline on Diagnostics and Therapy of Clinically Non-Functioning Pituitary Tumors. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2021, 129, 250-264.	1.2	12
31	Case Report: Abdominal Lymph Node Metastases of Parathyroid Carcinoma: Diagnostic Workup, Molecular Diagnosis, and Clinical Management. <i>Frontiers in Endocrinology</i> , 2021, 12, 643328.	3.5	12
32	Epithelial and Mesenchymal Markers in Adrenocortical Tissues: How Mesenchymal Are Adrenocortical Tissues?. <i>Cancers</i> , 2021, 13, 1736.	3.7	5
33	What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question. <i>Journal of Personalized Medicine</i> , 2021, 11, 269.	2.5	14
34	Incidence of hyperkalemia during hypertonic saline test for the diagnosis of diabetes insipidus. <i>Endocrine Connections</i> , 2021, 10, 401-409.	1.9	2
35	Treatment of symptomatic hyponatremia with hypertonic saline: a real-life observational study. <i>European Journal of Endocrinology</i> , 2021, 184, 647-655.	3.7	19
36	Oxytocin Levels in Response to Pituitary Provocation Tests in Healthy Volunteers. <i>Journal of the Endocrine Society</i> , 2021, 5, A631-A631.	0.2	0

#	ARTICLE	IF	CITATIONS
37	International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. <i>Nature Reviews Endocrinology</i> , 2021, 17, 435-444.	9.6	80
38	Method-Specific Cortisol and Dexamethasone Thresholds Increase Clinical Specificity of the Dexamethasone Suppression Test for Cushing Syndrome. <i>Clinical Chemistry</i> , 2021, 67, 998-1007.	3.2	18
39	A novel patient-derived cell line of adrenocortical carcinoma shows a pathogenic role of germline MUTYH mutation and high tumour mutational burden. <i>European Journal of Endocrinology</i> , 2021, 184, 823-835.	3.7	20
40	The role of regulated necrosis in endocrine diseases. <i>Nature Reviews Endocrinology</i> , 2021, 17, 497-510.	9.6	35
41	High expression of Sterol-O-Acyl transferase 1 (SOAT1), an enzyme involved in cholesterol metabolism, is associated with earlier biochemical recurrence in high risk prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, , .	3.9	10
42	Mass spectrometry imaging identifies metabolic patterns associated with malignant potential in pheochromocytoma and paraganglioma. <i>European Journal of Endocrinology</i> , 2021, 185, 179-191.	3.7	12
43	Novel CYP11B-ligand [123/131]IMAZA as promising theranostic tool for adrenocortical tumors: comprehensive preclinical characterization and first clinical experience. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, , 1.	6.4	7
44	Case Report: Consecutive Adrenal Cushing's Syndrome and Cushing's Disease in a Patient With Somatic CTNNB1, USP8, and NR3C1 Mutations. <i>Frontiers in Endocrinology</i> , 2021, 12, 731579.	3.5	5
45	FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale. <i>Frontiers in Endocrinology</i> , 2021, 12, 712107.	3.5	16
46	Adjuvant platinum-based chemotherapy in radically resected adrenocortical carcinoma: a cohort study. <i>British Journal of Cancer</i> , 2021, 125, 1233-1238.	6.4	14
47	Real world efficacy and safety of multi-tyrosine kinase inhibitors in radioiodine refractory thyroid cancer. <i>Thyroid</i> , 2021, 31, 1531-1541.	4.5	11
48	Management of Patients With Glucocorticoid-Related Diseases and COVID-19. <i>Frontiers in Endocrinology</i> , 2021, 12, 705214.	3.5	15
49	Identifying New Potential Biomarkers in Adrenocortical Tumors Based on mRNA Expression Data Using Machine Learning. <i>Cancers</i> , 2021, 13, 4671.	3.7	12
50	Oxytocin levels in response to pituitary provocation tests in healthy volunteers. <i>European Journal of Endocrinology</i> , 2021, 185, 355-364.	3.7	5
51	Analysis of Telomere Maintenance Related Genes Reveals NOP10 as a New Metastatic-Risk Marker in Pheochromocytoma/Paraganglioma. <i>Cancers</i> , 2021, 13, 4758.	3.7	14
52	Plasma Metabolome Profiling for the Diagnosis of Catecholamine Producing Tumors. <i>Frontiers in Endocrinology</i> , 2021, 12, 722656.	3.5	7
53	Simulation-Based Interpretation of Therapeutically Monitored Cabozantinib Plasma Concentration in Advanced Adrenocortical Carcinoma with Hemodialysis. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 706-711.	2.0	0
54	Confirmatory testing of primary aldosteronism with saline infusion test and LC-MS/MS. <i>European Journal of Endocrinology</i> , 2021, 184, 167-178.	3.7	11

#	ARTICLE	IF	CITATIONS
55	Rationale and design of the cardiovascular status in patients with endogenous cortisol excess study (CV-CORT-EX): a prospective non-interventional follow-up study. <i>BMC Endocrine Disorders</i> , 2021, 21, 11.	2.2	2
56	Plasma metanephrines and prospective prediction of tumor location, size and mutation type in patients with pheochromocytoma and paraganglioma. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 353-363.	2.3	32
57	6â€fLimited effects of bariatric surgery in patients with craniopharyngioma â€“ bariatric surgery as a â€œneurosurgicalâ€•intervention?. <i>Adipositas - Ursachen Folgeerkrankungen Therapie</i> , 2021, 15, .	0.2	0
58	Adrenocortical Carcinoma in Childhood: A Systematic Review. <i>Cancers</i> , 2021, 13, 5266.	3.7	12
59	The role of molecular profiling in adrenocortical carcinoma. <i>Clinical Endocrinology</i> , 2021, , .	2.4	4
60	Expression of the Chemokine Receptor CCR7 in the Normal Adrenal Gland and Adrenal Tumors and Its Correlation with Clinical Outcome in Adrenocortical Carcinoma. <i>Cancers</i> , 2021, 13, 5693.	3.7	1
61	Role of FGF Receptors and Their Pathways in Adrenocortical Tumors and Possible Therapeutic Implications. <i>Frontiers in Endocrinology</i> , 2021, 12, 795116.	3.5	2
62	Urine Steroid Metabolomics as a Novel Tool for Detection of Recurrent Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e307-e318.	3.6	45
63	Objective Response and Prolonged Disease Control of Advanced Adrenocortical Carcinoma with Cabozantinib. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1461-1468.	3.6	39
64	Response to Letter to the Editor: â€œCT Characteristics of Pheochromocytoma: Relevance for the Evaluation of Adrenal Incidentalomaâ€•. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3842-e3843.	3.6	0
65	Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study. <i>Lancet Diabetes and Endocrinology</i> , the, 2020, 8, 773-781.	11.4	129
66	Sino-European Differences in the Genetic Landscape and Clinical Presentation of Pheochromocytoma and Paraganglioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3295-3307.	3.6	34
67	RNA Sequencing and Somatic Mutation Status of Adrenocortical Tumors: Novel Pathogenetic Insights. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e4459-e4473.	3.6	24
68	Impact of the Chemokine Receptors CXCR4 and CXCR7 on Clinical Outcome in Adrenocortical Carcinoma. <i>Frontiers in Endocrinology</i> , 2020, 11, 597878.	3.5	18
69	Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma. , 2020, 8, e000469.		59
70	Next-generation therapies for adrenocortical carcinoma. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2020, 34, 101434.	4.7	61
71	Active steroid hormone synthesis renders adrenocortical cells highly susceptible to type II ferroptosis induction. <i>Cell Death and Disease</i> , 2020, 11, 192.	6.3	39
72	Cancer-testis Antigen FATE1 Expression in Adrenocortical Tumors Is Associated with A Pervasive Autoimmune Response and Is A Marker of Malignancy in Adult, but Not Children, <i>ACC. Cancers</i> , 2020, 12, 689.	3.7	14

#	ARTICLE	IF	CITATIONS
73	Early Postoperative Circulating miR-483-5p Is a Prognosis Marker for Adrenocortical Cancer. <i>Cancers</i> , 2020, 12, 724.	3.7	16
74	Glucocorticoid Excess in Patients with Pheochromocytoma Compared with Paraganglioma and Other Forms of Hypertension. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3374-e3383.	3.6	17
75	Effects of Germline CYP2W1*6 and CYP2B6*6 Single Nucleotide Polymorphisms on Mitotane Treatment in Adrenocortical Carcinoma: A Multicenter ENSAT Study. <i>Cancers</i> , 2020, 12, 359.	3.7	23
76	Bone Metastases in Medullary Thyroid Carcinoma: High Morbidity and Poor Prognosis Associated With Osteolytic Morphology. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2239-e2246.	3.6	10
77	Toward a Medical Gastric Bypass: Chronic Feeding Studies With Liraglutide + PYY3-36 Combination Therapy in Diet-Induced Obese Rats. <i>Frontiers in Endocrinology</i> , 2020, 11, 598843.	3.5	10
78	A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma. <i>Investigational New Drugs</i> , 2020, 38, 1421-1429.	2.6	33
79	Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2642-2653.	3.6	18
80	Intratumor heterogeneity of prognostic DNA-based molecular markers in adrenocortical carcinoma. <i>Endocrine Connections</i> , 2020, 9, 705-714.	1.9	10
81	Clinical spectrum of primary adrenal lymphoma: results of a multicenter cohort study. <i>European Journal of Endocrinology</i> , 2020, 183, 453-462.	3.7	18
82	HIF2 α supports pro-metastatic behavior in pheochromocytomas/paragangliomas. <i>Endocrine-Related Cancer</i> , 2020, 27, 625-640.	3.1	33
83	Heat Shock Protein 90 as a Prognostic Marker and Therapeutic Target for Adrenocortical Carcinoma. <i>Frontiers in Endocrinology</i> , 2019, 10, 487.	3.5	14
84	Value of Molecular Classification for Prognostic Assessment of Adrenocortical Carcinoma. <i>JAMA Oncology</i> , 2019, 5, 1440.	7.1	57
85	Arginine-stimulated copeptin measurements in the differential diagnosis of diabetes insipidus: a prospective diagnostic study. <i>Lancet, The</i> , 2019, 394, 587-595.	13.7	97
86	Driver mutations in USP8 wild-type Cushing's disease. <i>Neuro-Oncology</i> , 2019, 21, 1273-1283.	1.2	65
87	Exquisite sensitivity of adrenocortical carcinomas to induction of ferroptosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 22269-22274.	7.1	81
88	Synergistic Highly Potent Targeted Drug Combinations in Different Pheochromocytoma Models Including Human Tumor Cultures. <i>Endocrinology</i> , 2019, 160, 2600-2617.	2.8	24
89	Prognostic Relevance of Steroid Sulfation in Adrenocortical Carcinoma Revealed by Molecular Phenotyping Using High-Resolution Mass Spectrometry Imaging. <i>Clinical Chemistry</i> , 2019, 65, 1276-1286.	3.2	19
90	Alterations in Protein Kinase A Substrate Specificity as a Potential Cause of Cushing Syndrome. <i>Endocrinology</i> , 2019, 160, 447-459.	2.8	32

#	ARTICLE	IF	CITATIONS
91	Impact of USP8 Gene Mutations on Protein Deregulation in Cushing Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2535-2546.	3.6	29
92	GLP-1 and PYY3-36 reduce high-fat food preference additively after Roux-en-Y gastric bypass in diet-induced obese rats. <i>Surgery for Obesity and Related Diseases</i> , 2019, 15, 1483-1492.	1.2	20
93	Impact of 123I-MIBG Scintigraphy on Clinical Decision-Making in Pheochromocytoma and Paraganglioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 3812-3820.	3.6	19
94	Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2367-2374.	3.6	103
95	The Adrenal Gland: Central Relay in Health and Disease. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, 81-83.	1.2	5
96	The New Genetic Landscape of Cushing's Disease: Deubiquitinases in the Spotlight. <i>Cancers</i> , 2019, 11, 1761.	3.7	27
97	Volumetric and texture analysis of pretherapeutic 18F-FDG PET can predict overall survival in medullary thyroid cancer patients treated with Vandetanib. <i>Endocrine</i> , 2019, 63, 293-300.	2.3	13
98	CT Characteristics of Pheochromocytoma: Relevance for the Evaluation of Adrenal Incidentaloma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 312-318.	3.6	96
99	Patterns of Lymph Node Recurrence in Adrenocortical Carcinoma: Possible Implications for Primary Surgical Treatment. <i>Annals of Surgical Oncology</i> , 2019, 26, 531-538.	1.5	22
100	Advanced Adrenocortical Carcinoma – What to do when First-Line Therapy Fails?. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, 109-116.	1.2	43
101	Treatment of Refractory Adrenocortical Carcinoma with Thalidomide: Analysis of 27 Patients from the European Network for the Study of Adrenal Tumours Registry. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, 578-584.	1.2	15
102	Hsp90 inhibition in adrenocortical carcinoma: Limited drug synergism with mitotane. <i>Molecular and Cellular Endocrinology</i> , 2019, 480, 36-41.	3.2	8
103	Adrenomedullary function, obesity and permissive influences of catecholamines on body mass in patients with chromaffin cell tumours. <i>International Journal of Obesity</i> , 2019, 43, 263-275.	3.4	12
104	Plasma steroid metabolome profiling for the diagnosis of adrenocortical carcinoma. <i>European Journal of Endocrinology</i> , 2019, 180, 117-125.	3.7	59
105	The challenges of sodium measurements: indirect versus direct ion-selective method. <i>European Journal of Endocrinology</i> , 2019, 181, 193-199.	3.7	13
106	Pheochromocytoma and paraganglioma: clinical feature-based disease probability in relation to catecholamine biochemistry and reason for disease suspicion. <i>European Journal of Endocrinology</i> , 2019, 181, 409-420.	3.7	58
107	Metabolic impact of pheochromocytoma/paraganglioma: targeted metabolomics in patients before and after tumor removal. <i>European Journal of Endocrinology</i> , 2019, 181, 647-657.	3.7	19
108	OR29-2 Mild Autonomous Cortisol Excess (MACE) in Adrenal Incidentalomas - Metabolic Risk Profile and Urinary Steroid Metabolome Analysis in 1208 Prospectively Recruited Patients. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.2	0

#	ARTICLE	IF	CITATIONS
109	Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 1686-1695.	3.6	105
110	Release and Decay Kinetics of Copeptin vs AVP in Response to Osmotic Alterations in Healthy Volunteers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 505-513.	3.6	65
111	Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma. <i>Hypertension</i> , 2018, 71, 317-325.	2.7	77
112	High-Resolution Tissue Mass Spectrometry Imaging Reveals a Refined Functional Anatomy of the Human Adult Adrenal Gland. <i>Endocrinology</i> , 2018, 159, 1511-1524.	2.8	37
113	Predictive Value of ¹⁸ F-FDG PET in Patients with Advanced Medullary Thyroid Carcinoma Treated with Vandetanib. <i>Journal of Nuclear Medicine</i> , 2018, 59, 756-761.	5.0	26
114	ERCC1 as predictive biomarker to platinum-based chemotherapy in adrenocortical carcinomas. <i>European Journal of Endocrinology</i> , 2018, 178, 181-188.	3.7	15
115	Targeted Molecular Analysis in Adrenocortical Carcinomas: A Strategy Toward Improved Personalized Prognostication. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 4511-4523.	3.6	92
116	Impact of chronic hyponatremia on neurocognitive and neuromuscular function. <i>European Journal of Clinical Investigation</i> , 2018, 48, e13022.	3.4	27
117	A Copeptin-Based Approach in the Diagnosis of Diabetes Insipidus. <i>New England Journal of Medicine</i> , 2018, 379, 428-439.	27.0	180
118	European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. <i>European Journal of Endocrinology</i> , 2018, 179, G1-G46.	3.7	559
119	Adrenocortical incidentalomas and bone: from molecular insights to clinical perspectives. <i>Endocrine</i> , 2018, 62, 506-516.	2.3	11
120	Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients. <i>Genetics in Medicine</i> , 2018, 20, 1652-1662.	2.4	45
121	Biochemical Diagnosis of Chromaffin Cell Tumors in Patients at High and Low Risk of Disease: Plasma versus Urinary Free or Deconjugated O-Methylated Catecholamine Metabolites. <i>Clinical Chemistry</i> , 2018, 64, 1646-1656.	3.2	121
122	Surviving ectopic Cushing's syndrome: quality of life, cardiovascular and metabolic outcomes in comparison to Cushing's disease during long-term follow-up. <i>European Journal of Endocrinology</i> , 2018, 179, 109-116.	3.7	24
123	Missed clinical clues in patients with pheochromocytoma/paraganglioma discovered by imaging. <i>Endocrine Connections</i> , 2018, 7, 1168-1177.	1.9	11
124	FGF-21 levels in polyuria-polydipsia syndrome. <i>Endocrine Connections</i> , 2018, 7, 1501-1506.	1.9	0
125	Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. <i>Cancer Cell</i> , 2017, 31, 181-193.	16.8	532
126	Dosage-dependent regulation of VAV2 expression by steroidogenic factor-1 drives adrenocortical carcinoma cell invasion. <i>Science Signaling</i> , 2017, 10, .	3.6	35

#	ARTICLE	IF	CITATIONS
127	Topoisomerase 2 α and thymidylate synthase expression in adrenocortical cancer. <i>Endocrine-Related Cancer</i> , 2017, 24, 319-327.	3.1	24
128	Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1358-1365.	3.6	108
129	Plasma methoxytyramine: clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma. <i>European Journal of Endocrinology</i> , 2017, 177, 103-113.	3.7	82
130	Characteristics of Pediatric vs Adult Pheochromocytomas and Paragangliomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1122-1132.	3.6	120
131	Investigating the Chemokine Receptor 4 as Potential Theranostic Target in Adrenocortical Cancer Patients. <i>Clinical Nuclear Medicine</i> , 2017, 42, e29-e34.	1.3	60
132	Cortisol-related metabolic alterations assessed by mass spectrometry assay in patients with Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2017, 177, 227-237.	3.7	23
133	Differential expression of the protein kinase A subunits in normal adrenal glands and adrenocortical adenomas. <i>Scientific Reports</i> , 2017, 7, 49.	3.3	17
134	Steroid Profiling for Adrenocortical Disorders: A Pathway for Omics-Based Diagnostics. <i>Clinical Chemistry</i> , 2017, 63, 1787-1789.	3.2	8
135	Gemcitabine-Based Chemotherapy in Adrenocortical Carcinoma: A Multicenter Study of Efficacy and Predictive Factors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 4323-4332.	3.6	79
136	Assessment of VAV2 Expression Refines Prognostic Prediction in Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3491-3498.	3.6	33
137	PheoSeq. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 575-588.	2.8	63
138	Outcome after resection of Adrenocortical Carcinoma liver metastases: a retrospective study. <i>BMC Cancer</i> , 2017, 17, 522.	2.6	29
139	Livin/BIRC7 expression as malignancy marker in adrenocortical tumors. <i>Oncotarget</i> , 2017, 8, 9323-9338.	1.8	27
140	Laparoskopische Adrenaektomie. , 2017, , 187-195.		0
141	Inhibition of Cholesterol Esterification in the Adrenal Gland by ATR101/PD132301 α 2, A Promising Case of Drug Repurposing. <i>Endocrinology</i> , 2016, 157, 1719-1721.	2.8	5
142	Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. <i>European Journal of Endocrinology</i> , 2016, 175, G1-G34.	3.7	1,173
143	DNA methylation is an independent prognostic marker of survival in adrenocortical cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 102, jc.2016-3205.	3.6	44
144	Expression of 11 β -hydroxysteroid-dehydrogenase type 2 in human thymus. <i>Steroids</i> , 2016, 110, 35-40.	1.8	6

#	ARTICLE	IF	CITATIONS
145	Assessment of tumor heterogeneity in treatment-naïve adrenocortical cancer patients using 18F-FDG positron emission tomography. <i>Endocrine</i> , 2016, 53, 791-800.	2.3	8
146	Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. <i>Cancer Cell</i> , 2016, 29, 723-736.	16.8	482
147	MANAGEMENT OF ENDOCRINE DISEASE: Imaging for the diagnosis of malignancy in incidentally discovered adrenal masses: a systematic review and meta-analysis. <i>European Journal of Endocrinology</i> , 2016, 175, R51-R64.	3.7	171
148	<scp>FATE</scp> 1 antagonizes calcium– and drug– induced apoptosis by uncoupling <scp>ER</scp> and mitochondria. <i>EMBO Reports</i> , 2016, 17, 1264-1280.	4.5	102
149	Preclinical progress and first translational steps for a liposomal chemotherapy protocol against adrenocortical carcinoma. <i>Endocrine-Related Cancer</i> , 2016, 23, 825-837.	3.1	17
150	DIAGNOSIS OF ENDOCRINE DISEASE: The diagnostic performance of adrenal biopsy: a systematic review and meta-analysis. <i>European Journal of Endocrinology</i> , 2016, 175, R65-R80.	3.7	97
151	Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells. <i>Hormones and Cancer</i> , 2016, 7, 345-355.	4.9	12
152	Genetic Landscape of Sporadic Unilateral Adrenocortical Adenomas Without PRKACA p.Leu206Arg Mutation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 3526-3538.	3.6	65
153	The impact of external social and internal personal forces on consumers’ brand community engagement on Facebook. <i>Journal of Product and Brand Management</i> , 2016, 25, 409-423.	4.3	70
154	Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma: results of a multicenter study in Germany. <i>European Journal of Endocrinology</i> , 2016, 175, 521-529.	3.7	90
155	Salvage Treatment of Adrenocortical Carcinoma with Trofosfamide. <i>Hormones and Cancer</i> , 2016, 7, 211-218.	4.9	16
156	Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma. <i>European Journal of Endocrinology</i> , 2016, 174, 343-353.	3.7	20
157	Landscape of somatic mutations in sporadic GH-secreting pituitary adenomas. <i>European Journal of Endocrinology</i> , 2016, 174, 363-372.	3.7	100
158	High evening salivary cortisol is an independent predictor of increased mortality risk in patients with systolic heart failure. <i>International Journal of Cardiology</i> , 2016, 203, 69-73.	1.7	22
159	Consumer response to online/offline price differentiation. <i>Journal of Retailing and Consumer Services</i> , 2016, 28, 137-148.	9.4	56
160	Recurrent EZH1 mutations are a second hit in autonomous thyroid adenomas. <i>Journal of Clinical Investigation</i> , 2016, 126, 3383-3388.	8.2	66
161	Lack of Ubiquitin Specific Protease 8 (USP8) Mutations in Canine Corticotroph Pituitary Adenomas. <i>PLoS ONE</i> , 2016, 11, e0169009.	2.5	7
162	Dyslipidemia causes overestimation of plasma mitotane measurements. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2016, 2016, 150135.	0.5	3

#	ARTICLE	IF	CITATIONS
163	The Treatment of Well-Differentiated Thyroid Carcinoma. Deutsches Ärztblatt International, 2015, 112, 452-8.	0.9	40
164	Lack of utility of SDHB mutation testing in adrenergic metastatic pheochromocytoma. European Journal of Endocrinology, 2015, 172, 89-95.	3.7	17
165	Frequency and Clinical Correlates of Somatic Ying Yang 1 Mutations in Sporadic Insulinomas. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E776-E782.	3.6	42
166	Pregnancy in Women Previously Treated for an Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 4604-4611.	3.6	19
167	Major Prognostic Role of Ki67 in Localized Adrenocortical Carcinoma After Complete Resection. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 841-849.	3.6	274
168	Prognostic Value of Aldosterone and Cortisol in Patients Hospitalized for Acutely Decompensated Chronic Heart Failure With and Without Mineralocorticoid Receptor Antagonism. Journal of Cardiac Failure, 2015, 21, 208-216.	1.7	17
169	High Incidence of Adrenal Crisis in Educated Patients With Chronic Adrenal Insufficiency: A Prospective Study. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 407-416.	3.6	308
170	Expression of <sc>LIN</sc>28 and its regulatory micro<sc>RNA</sc>s in adult adrenocortical cancer. Clinical Endocrinology, 2015, 82, 481-488.	2.4	25
171	Measurements of plasma metanephrines by immunoassay vs liquid chromatography with tandem mass spectrometry for diagnosis of pheochromocytoma. European Journal of Endocrinology, 2015, 172, 251-260.	3.7	47
172	Computed tomography criteria for discrimination of adrenal adenomas and adrenocortical carcinomas: analysis of the German ACC registry. European Journal of Endocrinology, 2015, 172, 415-422.	3.7	43
173	Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncology, The, 2015, 16, 426-435.	10.7	272
174	The New Molecular Landscape of Cushing's Disease. Trends in Endocrinology and Metabolism, 2015, 26, 573-583.	7.1	26
175	Treatment of malignant pheochromocytoma with a combination of cyclophosphamide, vincristine and dacarbazine: own experience and overview of the contemporary literature. Clinical Endocrinology, 2015, 82, 84-90.	2.4	21
176	Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer. Endocrine-Related Cancer, 2015, 22, 877-887.	3.1	58
177	Decoding the genetic basis of Cushing's disease: USP8 in the spotlight. European Journal of Endocrinology, 2015, 173, M73-M83.	3.7	46
178	Notch1 pathway in adrenocortical carcinomas: correlations with clinical outcome. Endocrine-Related Cancer, 2015, 22, 531-543.	3.1	27
179	Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells. Endocrinology, 2015, 156, 3895-3908.	2.8	153
180	Selling luxury goods online: effects of online accessibility and price display. International Journal of Retail and Distribution Management, 2015, 43, 1065-1082.	4.7	30

#	ARTICLE	IF	CITATIONS
181	Role of Endocrine Gland-Derived Vascular Endothelial Growth Factor (EG-VEGF) and Its Receptors in Adrenocortical Tumors. <i>Hormones and Cancer</i> , 2015, 6, 225-236.	4.9	8
182	A case report of a solitary pancreatic metastasis of an adrenocortical carcinoma. <i>BMC Surgery</i> , 2015, 15, 93.	1.3	3
183	Mutations in the deubiquitinase gene USP8 cause Cushing's disease. <i>Nature Genetics</i> , 2015, 47, 31-38.	21.4	450
184	Hypertension and hypertensive cardiomyopathy in patients with a relapse-free history of pheochromocytoma. <i>Clinical Endocrinology</i> , 2015, 82, 188-196.	2.4	5
185	Abstract 2976: Comprehensive Pan-Genomic characterization of adrenocortical carcinoma. , 2015, , .		2
186	ATR-101 phase 1 clinical study for adrenocortical carcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS4585-TPS4585.	1.6	3
187	Inducible Knock-Down of the Mineralocorticoid Receptor in Mice Disturbs Regulation of the Renin-Angiotensin-Aldosterone System and Attenuates Heart Failure Induced by Pressure Overload. <i>PLoS ONE</i> , 2015, 10, e0143954.	2.5	12
188	CYP2W1 Is Highly Expressed in Adrenal Glands and Is Positively Associated with the Response to Mitotane in Adrenocortical Carcinoma. <i>PLoS ONE</i> , 2014, 9, e105855.	2.5	41
189	Novel Somatic Mutations in the Catalytic Subunit of the Protein Kinase A as a Cause of Adrenal Cushing's Syndrome: A European Multicentric Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E2093-E2100.	3.6	92
190	PKA catalytic subunit mutations in adrenocortical Cushing's adenoma impair association with the regulatory subunit. <i>Nature Communications</i> , 2014, 5, 5680.	12.8	63
191	Extending downward is not always bad: Parent brand evaluations after brand extension to higher and lower price and quality levels. <i>Journal of Brand Management</i> , 2014, 21, 303-324.	3.5	23
192	EJE PRIZE 2014: Current and evolving treatment options in adrenocortical carcinoma: where do we stand and where do we want to go?. <i>European Journal of Endocrinology</i> , 2014, 171, R1-R11.	3.7	37
193	Less common genotype variants of TP53 polymorphisms are associated with poor outcome in adult patients with adrenocortical carcinoma. <i>European Journal of Endocrinology</i> , 2014, 170, 707-717.	3.7	8
194	Prognostic Role of Overt Hypercortisolism in Completely Operated Patients with Adrenocortical Cancer. <i>European Urology</i> , 2014, 65, 832-838.	1.9	121
195	Does bariatric surgery change olfactory perception? Results of the early postoperative course. <i>International Journal of Colorectal Disease</i> , 2014, 29, 253-260.	2.2	23
196	Levodopa therapy in Parkinson's disease: influence on liquid chromatographic tandem mass spectrometric-based measurements of plasma and urinary normetanephrine, metanephrine and methoxytyramine. <i>Annals of Clinical Biochemistry</i> , 2014, 51, 38-46.	1.6	26
197	A Copeptin-Based Classification of the Osmoregulatory Defects in the Syndrome of Inappropriate Antidiuresis. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 2376-2383.	6.1	62
198	Integrated genomic characterization of adrenocortical carcinoma. <i>Nature Genetics</i> , 2014, 46, 607-612.	21.4	560

#	ARTICLE	IF	CITATIONS
199	Constitutive Activation of PKA Catalytic Subunit in Adrenal Cushing's Syndrome. <i>New England Journal of Medicine</i> , 2014, 370, 1019-1028.	27.0	355
200	Adrenal Function After Adrenalectomy for Subclinical Hypercortisolism and Cushing's Syndrome: A Systematic Review of the Literature. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 2637-2645.	3.6	99
201	No endogenous ouabain is detectable in human plasma by ultra-sensitive UPLC-MS/MS. <i>Clinica Chimica Acta</i> , 2014, 431, 87-92.	1.1	58
202	Thyroid Function, Cardiovascular Events, and Mortality in Diabetic Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 2014, 63, 988-996.	1.9	57
203	International randomized, double-blind, placebo-controlled, phase 3 study of linsitinib (OSI-906, L) in patients (pts) with locally advanced or metastatic adrenocortical carcinoma (ACC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 4507-4507.	1.6	1
204	Safety and tolerability of sorafenib for treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC): Detailed analyses from the phase III DECISION trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 6062-6062.	1.6	4
205	Prognostic factors of overall survival of stage III or IV adrenocortical carcinomas (ACC): A multicenter ENS@T study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4106-4106.	1.6	0
206	Abstract LB-182: Constitutive activation of PRKACA in adrenal Cushing's syndrome. , 2014, , .		0
207	Update in Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 4551-4564.	3.6	346
208	Mitotane Therapy in Adrenocortical Cancer Induces CYP3A4 and Inhibits 5 α -Reductase, Explaining the Need for Personalized Glucocorticoid and Androgen Replacement. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 161-171.	3.6	131
209	Simultaneous liquid chromatography tandem mass spectrometric determination of urinary free metanephrines and catecholamines, with comparisons of free and deconjugated metabolites. <i>Clinica Chimica Acta</i> , 2013, 418, 50-58.	1.1	82
210	Bariatric surgery for morbid obesity in craniopharyngioma. <i>Clinical Endocrinology</i> , 2013, 78, 385-390.	2.4	37
211	Functional Characterization of Adrenal Lesions Using [123I]IMTO-SPECT/CT. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 1508-1518.	3.6	47
212	Prognostic impact of subclinical thyroid dysfunction in heart failure. <i>International Journal of Cardiology</i> , 2013, 168, 300-305.	1.7	57
213	[123I]Iodometomidate Imaging in Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 2755-2764.	3.6	45
214	Luxury web atmospherics: an examination of homepage design. <i>International Journal of Retail and Distribution Management</i> , 2013, 41, 901-916.	4.7	32
215	The Role of Surgery in the Management of Recurrent Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 181-191.	3.6	132
216	Aldosterone and cortisol affect the risk of sudden cardiac death in haemodialysis patients. <i>European Heart Journal</i> , 2013, 34, 578-587.	2.2	46

#	ARTICLE	IF	CITATIONS
217	Reply to Letter. <i>Annals of Surgery</i> , 2013, 257, e15.	4.2	2
218	Single Nucleotide Polymorphism Array Profiling of Adrenocortical Tumors - Evidence for an Adenoma Carcinoma Sequence?. <i>PLoS ONE</i> , 2013, 8, e73959.	2.5	58
219	[¹³¹ I]Iodometomidate for Targeted Radionuclide Therapy of Advanced Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 914-922.	3.6	70
220	Ribonucleotide Reductase Large Subunit (<i>RRM1</i>) Gene Expression May Predict Efficacy of Adjuvant Mitotane in Adrenocortical Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 3452-3461.	7.0	64
221	Low SGK1 Expression in Human Adrenocortical Tumors Is Associated with ACTH-Independent Glucocorticoid Secretion and Poor Prognosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E2251-E2260.	3.6	38
222	Sunitinib in Refractory Adrenocortical Carcinoma: A Phase II, Single-Arm, Open-Label Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 3495-3503.	3.6	146
223	<i>TP53</i> Germline Mutations in Adult Patients with Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E476-E485.	3.6	89
224	Combination Chemotherapy in Advanced Adrenocortical Carcinoma. <i>New England Journal of Medicine</i> , 2012, 366, 2189-2197.	27.0	692
225	Impact of Lymphadenectomy on the Oncologic Outcome of Patients With Adrenocortical Carcinoma. <i>Annals of Surgery</i> , 2012, 255, 363-369.	4.2	146
226	Single Nucleotide Polymorphism Microarray Analysis in Cortisol-Secreting Adrenocortical Adenomas Identifies New Candidate Genes and Pathways. <i>Neoplasia</i> , 2012, 14, 206-213.	5.3	31
227	Adrenal Cancer: Scientific Advances. <i>Molecular and Cellular Endocrinology</i> , 2012, 351, 1.	3.2	2
228	Clinical impact of TP53 alterations in adrenocortical carcinomas. <i>Langenbeck's Archives of Surgery</i> , 2012, 397, 209-216.	1.9	39
229	Adrenocortical carcinoma: a clinician's update. <i>Nature Reviews Endocrinology</i> , 2011, 7, 323-335.	9.6	336
230	Sunitinib inhibits cell proliferation and alters steroidogenesis by down-regulation of HSD3B2 in adrenocortical carcinoma cells. <i>Frontiers in Endocrinology</i> , 2011, 2, 27.	3.5	29
231	Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. <i>Clinical Endocrinology</i> , 2011, 75, 585-591.	2.4	110
232	Contemporary Management of Adrenocortical Carcinoma. <i>European Urology</i> , 2011, 60, 1055-1065.	1.9	92
233	Metastatic Adrenocortical Carcinoma: Results of 56 Pulmonary Metastasectomies in 24 Patients. <i>Annals of Thoracic Surgery</i> , 2011, 92, 1965-1970.	1.3	37
234	Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10. <i>Human Mutation</i> , 2011, 32, 51-58.	2.5	117

#	ARTICLE	IF	CITATIONS
235	Plasma Concentrations of o,pâ€²DDD, o,pâ€²DDA, and o,pâ€²DDE as Predictors of Tumor Response to Mitotane in Adrenocortical Carcinoma: Results of a Retrospective ENS@T Multicenter Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 1844-1851.	3.6	160
236	Urine Steroid Metabolomics as a Biomarker Tool for Detecting Malignancy in Adrenal Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 3775-3784.	3.6	369
237	Î²-Catenin Activation Is Associated with Specific Clinical and Pathologic Characteristics and a Poor Outcome in Adrenocortical Carcinoma. <i>Clinical Cancer Research</i> , 2011, 17, 328-336.	7.0	128
238	Long-term effects of radiotherapy on cardiovascular risk factors in acromegaly. <i>European Journal of Endocrinology</i> , 2011, 164, 675-684.	3.7	6
239	T Cell Development Critically Depends on Prethymic Stromal Patched Expression. <i>Journal of Immunology</i> , 2011, 186, 3383-3391.	0.8	15
240	Copeptin in the Differential Diagnosis of the Polydipsia-Polyuria Syndromeâ€”Revisiting the Direct and Indirect Water Deprivation Tests. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 1506-1515.	3.6	147
241	Influence of Short-Term Glucocorticoid Therapy on Regulatory T Cells In Vivo. <i>PLoS ONE</i> , 2011, 6, e24345.	2.5	46
242	Recent advances in the diagnosis and treatment of adrenocortical carcinoma. <i>Regulatory Peptides</i> , 2010, 164, 2.	1.9	0
243	Laparoscopic Versus Open Adrenalectomy for Adrenocortical Carcinoma: Surgical and Oncologic Outcome in 152 Patients. <i>European Urology</i> , 2010, 58, 609-615.	1.9	246
244	Reply to Sebastien Gaujoux, Stephane Bonnet, Bertrand Doussetâ€™s Letter to the Editor re: David Brix, Bruno Allolio, Wiebke Fenske, et al. Laparoscopic Versus Open Adrenalectomy for Adrenocortical Carcinoma: Surgical and Oncologic Outcome in 152 Patients. <i>Eur Urol</i> 2010;58:609â€™15. <i>European Urology</i> , 2010, 58, e54.	1.9	0
245	Assessment of serumâ€™free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study. <i>Clinical Endocrinology</i> , 2010, 72, 305-311.	2.4	30
246	What is the best approach to an apparently nonmetastatic adrenocortical carcinoma?. <i>Clinical Endocrinology</i> , 2010, 73, 561-565.	2.4	40
247	Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. <i>European Journal of Endocrinology</i> , 2010, 162, 349-356.	3.7	119
248	Adjuvant Therapy in Patients With Adrenocortical Carcinoma: A Position of an International Panel. <i>Journal of Clinical Oncology</i> , 2010, 28, e401-e402.	1.6	95
249	Epidemiology of adrenal crisis in chronic adrenal insufficiency: the need for new prevention strategies. <i>European Journal of Endocrinology</i> , 2010, 162, 597-602.	3.7	274
250	Improved Survival in Patients with Stage II Adrenocortical Carcinoma Followed Up Prospectively by Specialized Centers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 4925-4932.	3.6	150
251	Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome. <i>Modern Pathology</i> , 2010, 23, 1596-1604.	5.5	46
252	High Diagnostic and Prognostic Value of Steroidogenic Factor-1 Expression in Adrenal Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, E161-E171.	3.6	196

#	ARTICLE	IF	CITATIONS
253	Deficits in the Management of Patients With Adrenocortical Carcinoma in Germany. Deutsches Ärzteblatt International, 2010, 107, 885-91.	0.9	44
254	Frequent incidental discovery of pheochromocytoma: data from a German cohort of 201 pheochromocytoma. European Journal of Endocrinology, 2009, 161, 355-361.	3.7	174
255	Clinical Predictors and Algorithm for the Genetic Diagnosis of Pheochromocytoma Patients. Clinical Cancer Research, 2009, 15, 6378-6385.	7.0	160
256	Potency and Tolerance of Calcitonin Stimulation with High-Dose Calcium<i>Versus</i>Pentagastrin in Normal Adults. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2970-2974.	3.6	82
257	Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma. Endocrine-Related Cancer, 2009, 16, 919-928.	3.1	71
258	Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy. Endocrine-Related Cancer, 2009, 16, 907-918.	3.1	63
259	New targets and therapeutic approaches for endocrine malignanciesâ†. , 2009, 123, 117-141.		97
260	Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma. Cancer, 2009, 115, 243-250.	4.1	597
261	Radiotherapy in adrenocortical carcinoma. Cancer, 2009, 115, 2816-2823.	4.1	165
262	Reply to Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma. Cancer, 2009, 115, 5848-5848.	4.1	5
263	Osteopontin stimulates invasion of NCIâ€h295 cells but is not associated with survival in adrenocortical carcinoma. Journal of Pathology, 2009, 218, 232-240.	4.5	13
264	Clinical management of adrenocortical carcinoma. Best Practice and Research in Clinical Endocrinology and Metabolism, 2009, 23, 273-289.	4.7	272
265	LONG-TERM OUTCOME OF LAPAROSCOPIC VERSUS OPEN ADRENALECTOMY FOR ADRENOCORTICAL CANCER. Journal of Urology, 2009, 181, 10-11.	0.4	0
266	Treatment of Advanced Adrenocortical Carcinoma with Erlotinib plus Gemcitabine. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2057-2062.	3.6	141
267	Silencing of the Mineralocorticoid Receptor by Ribonucleic Acid Interference in Transgenic Rats Disrupts Endocrine Homeostasis. Molecular Endocrinology, 2008, 22, 1304-1311.	3.7	13
268	Side Population Does Not Define Stem Cell-Like Cancer Cells in the Adrenocortical Carcinoma Cell Line NCI h295R. Endocrinology, 2008, 149, 1314-1322.	2.8	47
269	[123I]Iodometomidate for Molecular Imaging of Adrenocortical Cytochrome P450 Family 11B Enzymes. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2358-2365.	3.6	88
270	Impaired Subjective Health Status in 256 Patients with Adrenal Insufficiency on Standard Therapy Based on Cross-Sectional Analysis. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3912-3922.	3.6	242

#	ARTICLE	IF	CITATIONS
271	Vaccination against the Forkhead Family Transcription Factor Foxp3 Enhances Tumor Immunity. <i>Cancer Research</i> , 2007, 67, 371-380.	0.9	140
272	Adjuvant Mitotane Treatment for Adrenocortical Carcinoma. <i>New England Journal of Medicine</i> , 2007, 356, 2372-2380.	27.0	679
273	Consequences of Web-based service quality: Uncovering a multi-faceted chain of effects. <i>Journal of Interactive Marketing</i> , 2007, 21, 35-54.	6.2	108
274	Quality of Electronic Services. <i>Journal of Service Research</i> , 2006, 9, 19-37.	12.2	420
275	Adrenocortical Carcinoma: Clinical Update. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 2027-2037.	3.6	683
276	Dendritic cells as potential adjuvant for immunotherapy in adrenocortical carcinoma. <i>Clinical Endocrinology</i> , 2006, 65, 215-222.	2.4	24
277	Intraoperative haemodynamic stability in patients with pheochromocytoma ? minimally invasive vs conventional open surgery. <i>Clinical Endocrinology</i> , 2006, 65, 352-358.	2.4	28
278	A Dangerous Liaisonâ€”Pheochromocytoma in Patients with Malignant Disease. <i>Annals of Surgical Oncology</i> , 2006, 13, 1696-1701.	1.5	15
279	Comprehensive Mutation Scanning of NF1 in Apparently Sporadic Cases of Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 3478-3481.	3.6	53
280	Efficacy of Adjuvant Radiotherapy of the Tumor Bed on Local Recurrence of Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 4501-4504.	3.6	224
281	Peripheral administration of the N-terminal pro-opiomelanocortin fragment 1â€“28 to Pomcâ~/â~ mice reduces food intake and weight but does not affect adrenal growth or corticosterone production. <i>Journal of Endocrinology</i> , 2006, 190, 515-525.	2.6	29
282	Induction of CD4+ and CD8+ T-Cell Responses to the Human Stromal Antigen, Fibroblast Activation Protein: Implication for Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2005, 11, 5566-5571.	7.0	62
283	Evidence against a role of human airway trypsin-like protease â€“ the human analogue of the growth-promoting rat adrenal secretory protease â€“ in adrenal tumorigenesis. <i>European Journal of Endocrinology</i> , 2005, 152, 143-153.	3.7	17
284	AKT Is Highly Phosphorylated in Pheochromocytomas But Not in Benign Adrenocortical Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 4366-4370.	3.6	43
285	Peroxisome Proliferator-Activated Receptor-Î³ Agonists Suppress Adrenocortical Tumor Cell Proliferation and Induce Differentiation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 3886-3896.	3.6	67
286	Congenital Isolated Adrenocorticotropin Deficiency: An Underestimated Cause of Neonatal Death, Explained byTPITGene Mutations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 1323-1331.	3.6	116
287	Tumor Immunotherapy Targeting Fibroblast Activation Protein, a Product Expressed in Tumor-Associated Fibroblasts. <i>Cancer Research</i> , 2005, 65, 11156-11163.	0.9	148
288	The Adrenal Secretory Serine Protease AsP Is a Short Secretory Isoform of the Transmembrane Airway Trypsin-Like Protease. <i>Endocrinology</i> , 2004, 145, 1898-1905.	2.8	30

#	ARTICLE	IF	CITATIONS
289	Management of adrenocortical carcinoma. <i>Clinical Endocrinology</i> , 2004, 60, 273-287.	2.4	185
290	The pro-opiomelanocortin gene of the zebrafish (<i>Danio rerio</i>). <i>Biochemical and Biophysical Research Communications</i> , 2003, 303, 1121-1128.	2.1	47
291	Beyond Adrenal and Ovarian Androgen Generation: Increased Peripheral 5 α -Reductase Activity in Women with Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 2760-2766.	3.6	140
292	N-Terminal Proopiomelanocortin Acts as a Mitogen in Adrenocortical Tumor Cells and Decreases Adrenal Steroidogenesis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 2171-2179.	3.6	64
293	Service Orientation of a Retailer's Business Strategy: Dimensions, Antecedents, and Performance Outcomes. <i>Journal of Marketing</i> , 2002, 66, 86-101.	11.3	388
294	Angiotensin II type 1 receptor and ACTH receptor expression in human adrenocortical neoplasms. <i>Clinical Endocrinology</i> , 2001, 54, 627-632.	2.4	37
295	Octreotide LAR [®] treatment throughout pregnancy in an acromegalic woman. <i>Clinical Endocrinology</i> , 2001, 55, 411-415.	2.4	83
296	Dehydroepiandrosterone Replacement in Women with Adrenal Insufficiency: Effects on Body Composition, Serum Leptin, Bone Turnover, and Exercise Capacity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 1968-1972.	3.6	88
297	Dehydroepiandrosterone Replacement in Women with Adrenal Insufficiency: Effects on Body Composition, Serum Leptin, Bone Turnover, and Exercise Capacity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 1968-1972.	3.6	37
298	Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma. <i>Endocrine Abstracts</i> , 0, , .	0.0	1
299	Metyrapone Versus Osilodrostat in the Short-Term Therapy of Endogenous Cushing's Syndrome: Results From a Single Center Cohort Study. <i>Frontiers in Endocrinology</i> , 0, 13, .	3.5	5